WO2011156901A3 - Compounds, compositions and methods for treatment of multiple sclerosis - Google Patents

Compounds, compositions and methods for treatment of multiple sclerosis Download PDF

Info

Publication number
WO2011156901A3
WO2011156901A3 PCT/CA2011/000697 CA2011000697W WO2011156901A3 WO 2011156901 A3 WO2011156901 A3 WO 2011156901A3 CA 2011000697 W CA2011000697 W CA 2011000697W WO 2011156901 A3 WO2011156901 A3 WO 2011156901A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
compounds
methods
multiple sclerosis
treatment
Prior art date
Application number
PCT/CA2011/000697
Other languages
French (fr)
Other versions
WO2011156901A2 (en
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc. filed Critical Waratah Pharmaceuticals Inc.
Publication of WO2011156901A2 publication Critical patent/WO2011156901A2/en
Publication of WO2011156901A3 publication Critical patent/WO2011156901A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds, compositions, formulations and dosage forms comprising N-(Cyclopropylmethyl)-6-phenyl-4-(pyridin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, and methods for treating multiple sclerosis in a subject using same.
PCT/CA2011/000697 2010-06-17 2011-06-16 Compounds, compositions and methods for treatment of multiple sclerosis WO2011156901A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35576310P 2010-06-17 2010-06-17
US61/355,763 2010-06-17

Publications (2)

Publication Number Publication Date
WO2011156901A2 WO2011156901A2 (en) 2011-12-22
WO2011156901A3 true WO2011156901A3 (en) 2012-02-02

Family

ID=45348590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2011/000697 WO2011156901A2 (en) 2010-06-17 2011-06-16 Compounds, compositions and methods for treatment of multiple sclerosis

Country Status (1)

Country Link
WO (1) WO2011156901A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589106A1 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
CA2650711A1 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2650625A1 (en) * 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589106A1 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
CA2650711A1 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2650625A1 (en) * 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases

Also Published As

Publication number Publication date
WO2011156901A2 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
IL244974B (en) Film dosage compositions comprising buprenorphine and naloxone, film formulations comprising the same and use thereof for the preparation of medicaments for treating narcotic dependence
UA108087C2 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptane-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
MX2015008957A (en) Fluoro-[1,3]oxazines as bace1 inhibitors.
WO2013169704A3 (en) TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2014002171A (en) Combination treatments for hepatitis c.
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2013100567A8 (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
ZA201004214B (en) Dipeptidyl peptidase-iv inhibiting compounds,methods of preparing the same,and pharmaceutical compositions containing the same as active agent
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
EP2583969A4 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
WO2012021800A3 (en) Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2013062442A3 (en) Composition for the treatment of multiple sclerosis (variants)
IL210975A (en) Enfumafungin derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating fungal infections
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11794986

Country of ref document: EP

Kind code of ref document: A2